ERBB3 and neoplasm: To examine the ability of anti-HER3 antibodies to augment the combined action of osimertinib and cetuximab in the context of high ITH tumors, we employed two different PDX models, one derived from a primary tumor (Figure 6) and the other from a metastatic lesion (Figure 7).